Pyxis Oncology, Inc. (NASDAQ: PYXS) is a Healthcare company (Biotechnology) with a market capitalization of $172M. The Maz Rating grades it against the other companies in its sector.
Pyxis Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.44, Pyxis Oncology, Inc. trades at 15.2x sales and 2.8x book value. Over the last twelve months it generated about $11M of revenue and a net loss of $159M. It runs a gross margin of 99.8%, an operating margin of -807.8% and a net margin of -785.5%. It shows return on equity of -252.4%, return on invested capital of -151.9% and a free cash flow yield of -41.2%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $1.03 to $5.55, with a beta of 1.41.
Pyxis Oncology, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.